Literature DB >> 24316488

A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.

Ning Zhang1, Qiang Huo1, Xiaolong Wang1, Xi Chen1, Li Long1, Xiao Guan2, Liyu Jiang1, Tingting Ma1, Wenwei Hu3, Qifeng Yang4.   

Abstract

BACKGROUND: p63, homologous to p53, has been investigated to be involved in various aspects of tumorigenesis and cancer progression. Recently, we have identified a functional single nucleotide polymorphism (SNP) rs17506395 (T>G) in p63 which was associated with female reproduction and ovarian cancer development. The present study aimed to evaluate the association of rs17506395 genotypes with breast cancer susceptibility, clinicopathological characteristics and prognosis. PATIENTS AND METHODS: TaqMan assay was used to genotype the rs17506395 polymorphism. The expression of p63 mRNA was determined by quantitative reverse-transcription PCR (qRT-PCR). Unconditional logistic regression and univariate Cox hazard regression analyses were performed to evaluate the association of rs17506395 with breast cancer susceptibility and prognosis respectively.
RESULTS: First, we found that breast tumors with TT genotype exhibited higher level of p63 mRNA compared with other genotypes in breast cancer tissues, indicating that rs17506395 may be a functional single nucleotide polymorphism in breast cancer. Further investigation revealed that the presence of TT genotype was statistically correlated with increased risk for breast cancer, compared with genotypes containing the G allele (GG and GT). Moreover, a significant association between rs17506395 polymorphism and age at diagnosis and status of hormone receptor was observed. Consistently, prognostic analysis showed that patients carrying TT genotype represent unfavorable survival, suggesting that TT genotype may be a biomarker for poor prognosis in breast cancer.
CONCLUSION: Our data suggest that rs17506395 polymorphism can function as a risk factor and prognostic indicator for breast cancer, whereas precise mechanism underlying the function of this polymorphism needs further investigation.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; ER; HER2; HWE; Hardy–Weinberg equilibrium; IHC; PCR; PR; Prognosis; SNP; SNPs; Single nucleotide polymorphism; Susceptibility; estrogen receptor; human epidermal growth factor receptor 2; immunohistochemistry; p63; polymerase chain reaction; progesterone receptor; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2013        PMID: 24316488     DOI: 10.1016/j.gene.2013.11.038

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

1.  ΔNp63α induces the expression of FAT2 and Slug to promote tumor invasion.

Authors:  Tuyen T Dang; Jill M Westcott; Erin A Maine; Mohammed Kanchwala; Chao Xing; Gray W Pearson
Journal:  Oncotarget       Date:  2016-05-10

2.  Inflammation-Related Gene Polymorphisms Associated With Primary Immune Thrombocytopenia.

Authors:  Ju Li; Sai Ma; Linlin Shao; Chunhong Ma; Chengjiang Gao; Xiao-Hui Zhang; Ming Hou; Jun Peng
Journal:  Front Immunol       Date:  2017-06-28       Impact factor: 7.561

3.  p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors.

Authors:  Stefan Steurer; Claudia Riemann; Franziska Büscheck; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Anne Menz; Margit Fisch; Michael Rink; Christian Bernreuther; Patrick Lebok; Till S Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; David Dum; Ronald Simon; Sarah Minner; Eike Burandt; Rainer Krech; Till Krech; Andreas H Marx
Journal:  Biomark Res       Date:  2021-01-25

4.  Common polymorphic inversions at 17q21.31 and 8p23.1 associate with cancer prognosis.

Authors:  Carlos Ruiz-Arenas; Alejandro Cáceres; Victor Moreno; Juan R González
Journal:  Hum Genomics       Date:  2019-11-21       Impact factor: 4.639

5.  The TP63 Gene Polymorphism rs17506395 is Associated with Early Breast Cancer in Cameroon.

Authors:  Arnol T Z Tiofack; Gustave Simo; Elvis Ofon; Esther Dina-Bell; Chancelin M Kamla; Sidonie N Ananga; Tchamfong Roger; Theophile N Nana; Charlotte T Ngeufack; Adamou Fewou; Samuel Takongmo; Smiths Lueong
Journal:  Asian Pac J Cancer Prev       Date:  2020-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.